Lv1
48 积分 2022-11-22 加入
Research progress in OX40/OX40L in allergic diseases
13小时前
待确认
An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study
14小时前
已完结
345 Treatment with amlitelimab—a novel non-depleting, non-cytotoxic anti-OX40Ligand monoclonal antibody—reduces IL-22 serum levels in a phase 2a randomized, placebo-controlled trial in patients with moderate-to-severe atopic dermatitis
14小时前
已完结
Zalsupindole is a Nondissociative, Nonhallucinogenic Neuroplastogen with Therapeutic Effects Comparable to Ketamine and Psychedelics
1个月前
已完结
Vitiligo
1个月前
已完结
The immunology of vitiligo
1个月前
已完结
Advances in psoriasis research: From pathogenesis to therapeutics
3个月前
已完结
Pathogenesis, multi-omics research, and clinical treatment of psoriasis
3个月前
已完结
Targeting formyl peptide receptor 1 reduces brain inflammation and neurodegeneration
4个月前
已完结
Cutaneous ischemia‐reperfusion injury is exacerbated by IL‐36 receptor antagonist deficiency
5个月前
已完结
皖公网安备34019202002308
